株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大鬱病性障害 : パイプライン分析

Major Depressive Disorder - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232790
出版日 ページ情報 英文 201 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
大鬱病性障害 : パイプライン分析 Major Depressive Disorder - Pipeline Review, H2 2016
出版日: 2016年10月12日 ページ情報: 英文 201 Pages
概要

大鬱病性障害(MDD)は、気分的な落ち込みが広がり、ずっと続くのが特徴である精神障害で、低い自尊心や、通常であれば楽しい活動に対しても関心が持てなかったり、楽しさが感じられなかったりする状態を伴います。 症状は、動揺や落ち着きの無さ、イライラ、怒り、引きこもり、孤立感、疲労感とエネルギー不足、絶望感・無力感を感じる、自分に価値が無いと思う、罪悪感、自己嫌悪を感じる、以前だったら楽しめたことに対する興味や喜びを失う、突然食欲が変わる、体重がよく増減する、死や自殺を考える、集中できない、眠れないか寝過ぎるなどが挙げられます。

当レポートでは、大鬱病性障害の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

大鬱病性障害 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Aequus Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc
  • Angelini Group
  • Azevan Pharmaceuticals, Inc.
  • BioCrea GmbH
  • Bristol-Myers Squibb Company
  • Cerecor Inc.
  • e-Therapeutics Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Hua Medicine Ltd.
  • Intra-Cellular Therapies, Inc.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Lead Discovery Center GmbH
  • Luye Pharma Group Ltd.
  • Mapreg S.A.S.
  • Methylation Sciences Inc.
  • miCure Therapeutics Ltd.
  • 田辺三菱製薬
  • Naurex, Inc.
  • Neuralstem, Inc.
  • nLife Therapeutics, S.L.
  • 大塚ホールディングス
  • Pherin Pharmaceuticals, Inc.
  • Reviva Pharmaceuticals Inc.
  • Richter Gedeon Nyrt.
  • Saniona AB
  • 大日本住友製薬
  • Sunovion Pharmaceuticals Inc.
  • Suven Life Sciences Ltd.
  • VistaGen Therapeutics, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (アリピプラゾール + セルトラリン)
  • (サミドルファン + 塩酸ブプレノルフィン)
  • AN-788
  • アリピプラゾール
  • AV-101
  • AVP-786
  • バシムグルラント
  • ブレキシピプラゾール
  • 塩酸ビュープロピオン ER
  • カリプラジン
  • CERC-301
  • CERC-501
  • デスベンラファキシンコハク酸塩, SR
  • エディボキセチン塩酸塩
  • エディボキセチン塩酸塩
  • ITI-007
  • JNJ-42165279
  • JNJ-42847922
  • ルラシドン塩酸塩
  • LY-03005
  • LY-2940094
  • MAP-4343
  • MIN-117
  • miR-135
  • MSI-195
  • NLF-NEU
  • NP-11948
  • NRX-1074
  • NSI-189
  • onabotulinumtoxin A
  • PH-10
  • rapastinel
  • RP-5063
  • SEP-363856
  • シルクマブ
  • 大鬱病性障害向け FKBP51阻害小分子
  • 大鬱病性障害向け SLC6A15 標的小分子
  • 躁うつ病向けカッパオピオイド受容体作動薬
  • 中枢神経系疾患向けmGLUR5拮抗薬
  • 鬱病・大鬱病性障害向けNMDA受容体2B拮抗薬
  • 中枢神経系向けNMDA受容体およびCHRNA7拮抗薬
  • SNG-11
  • SRX-246
  • SUVN-911
  • tedatioxetine hydrobromide
  • 塩酸トラマドール
  • 塩酸トラゾドン
  • vortioxetine hydrobromide
  • VU-0431316

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8535IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape.

Major depressive disorder (MDD) is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. Symptoms of MDD include agitation, restlessness, and irritability, anger, becoming withdrawn or isolated, fatigue and lack of energy, feeling hopeless and helpless, worthless, guilty, self-hate, loss of interest or pleasure in activities that were once enjoyed, sudden change in appetite, often with weight gain or loss, thoughts of death or suicide, trouble concentrating and trouble sleeping or sleeping too much.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Major Depressive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Major Depressive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 18, 11, 1, 8 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Major Depressive Disorder.

Major Depressive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Major Depressive Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Major Depressive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Major Depressive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Major Depressive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Major Depressive Disorder (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Major Depressive Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Major Depressive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Major Depressive Disorder Overview
  • Therapeutics Development
  • Major Depressive Disorder - Therapeutics under Development by Companies
  • Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes
  • Major Depressive Disorder - Pipeline Products Glance
  • Major Depressive Disorder - Products under Development by Companies
  • Major Depressive Disorder - Products under Investigation by Universities/Institutes
  • Major Depressive Disorder - Companies Involved in Therapeutics Development
  • Major Depressive Disorder - Therapeutics Assessment
  • Drug Profiles
  • Major Depressive Disorder - Dormant Projects
  • Major Depressive Disorder - Discontinued Products
  • Major Depressive Disorder - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Major Depressive Disorder, H2 2016
  • Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Major Depressive Disorder - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Alkermes Plc, H2 2016
  • Major Depressive Disorder - Pipeline by Allergan Plc, H2 2016
  • Major Depressive Disorder - Pipeline by Angelini Group, H2 2016
  • Major Depressive Disorder - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by BioCrea GmbH, H2 2016
  • Major Depressive Disorder - Pipeline by BioLite, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Major Depressive Disorder - Pipeline by Cerecor Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Clera Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H2 2016
  • Major Depressive Disorder - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Johnson & Johnson, H2 2016
  • Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Major Depressive Disorder - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H2 2016
  • Major Depressive Disorder - Pipeline by Mapreg S.A.S., H2 2016
  • Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H2 2016
  • Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H2 2016
  • Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Major Depressive Disorder - Pipeline by Neuralstem, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H2 2016
  • Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Major Depressive Disorder - Pipeline by Saniona AB, H2 2016
  • Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Major Depressive Disorder - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Major Depressive Disorder - Pipeline by TRImaran Pharma, Inc., H2 2016
  • Major Depressive Disorder - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Major Depressive Disorder - Dormant Projects, H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..1), H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..2), H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..3), H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..4), H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..5), H2 2016
  • Major Depressive Disorder - Dormant Projects (Contd..6), H2 2016
  • Major Depressive Disorder - Discontinued Products, H2 2016
  • Major Depressive Disorder - Discontinued Products (Contd..1), H2 2016
  • Major Depressive Disorder - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Major Depressive Disorder, H2 2016
  • Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top